<DOC>
	<DOCNO>NCT00550004</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , double blind , placebo control , study six 28-day treatment cycle patient locally advance , unresectable , metastatic pancreatic cancer . The study conduct approximately 55 site North American , Europe , South America . Approximately 153 subject enrol randomization ( ratio 2:1 ) .</brief_summary>
	<brief_title>Phase II Study Evaluate Efficacy Safety RP101 Combination With Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Subjects must 18 year age old Not previously treat chemotherapy Pancreatic Cancer ECOG performance status 0 1 Life expectancy &gt; 3 month Documentation sit pancreatic disease within 28 day prior randomization Adequate hematological , renal , hepatic function Not pregnant nursing Fertile subject must practice medically approve method contraception Prior history malignant tumor Participation another investigational study within 4 week prior treatment start Major surgery within 14 day prior treatment start Radiation treatment within 28 day prior treatment start Uncontrolled cardiac atrial ventricular arrhythmias Gastrointestinal tract disease result inability take oral medication Known seropositive HIV , HBV , HCV Uncontrolled cancer pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Unresectable</keyword>
	<keyword>locally advanced</keyword>
	<keyword>metastatic pancreatic adenocarcinoma</keyword>
	<keyword>Stage III</keyword>
	<keyword>Stage IV</keyword>
</DOC>